Evidence map›Paper›PMID 30925910›Full record

ArticleBMC cancer2019

Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy.

Jun Ying, Danfei Zhou, Tongjie Gu, Jianda Huang, Haijian Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Impact of body composition parameters, age, and tumor staging on gastric cancer prognosis.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jun YingDepartment of Respiratory, Hwa Mei Hospital, University of Chinese Academy of Sciences, NO. 41, Xibei Street, Ningbo, 315000, Zhejiang Province, China.
Danfei ZhouDepartment of Respiratory, Hwa Mei Hospital, University of Chinese Academy of Sciences, NO. 41, Xibei Street, Ningbo, 315000, Zhejiang Province, China.
Tongjie GuDepartment of Respiratory, Hwa Mei Hospital, University of Chinese Academy of Sciences, NO. 41, Xibei Street, Ningbo, 315000, Zhejiang Province, China.
Jianda HuangDepartment of Respiratory, Hwa Mei Hospital, University of Chinese Academy of Sciences, NO. 41, Xibei Street, Ningbo, 315000, Zhejiang Province, China.
Haijian LiuDepartment of Respiratory, Hwa Mei Hospital, University of Chinese Academy of Sciences, NO. 41, Xibei Street, Ningbo, 315000, Zhejiang Province, China. liuhaijiantg@sina.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to identify potential predictive factors for the survival of advanced non small-cell lung cancer (NSCLC) patients undergoing first-line platinum-based chemotherapy.

methodsA total of 270 advanced NSCLC patients who underwent first-line platinum-based chemotherapy from June, 2011 to June, 2015 were enrolled. A receiver operating characteristic (ROC) curve analysis was used to evaluate the predictive value of the albumin-to-fibrinogen ratio (AFR) for overall survival (OS). The predictive factors for survival were evaluated by univariate and multivariate analyses via the Cox proportional hazards regression model. The OS and progression free survival (PFS) results were determined via the Kaplan-Meier method using the log-rank analysis.

resultsBased on the results of the ROC curve analysis, 8.02 was accepted as the cut-off AFR value for OS. The metastasis stage (M0 vs M1a/b, HR: 1.73, 95% CI: 1.15-2.59, P = 0.020) and AFR (≤8.02 vs > 8.02, HR: 1.80, 95% CI: 1.09-2.78, P = 0.025) were two independent risk factors for PFS by multivariate Cox regression analysis. The AFR (≤8.02 vs > 8.02, HR: 1.79, 95% CI: 1.11-2.59, P = 0.029) was a significant predictive factor for OS in advanced NSCLC patients. The PFS (P = 0.008) and OS (P = 0.003) in the high AFR group were significantly improved compared with those in the low AFR group via the Kaplan-Meier method using the log-rank analysis.

conclusionsThe AFR could be a potential effective predictive factor for the survival in advanced NSCLC patients undergoing first-line platinum-based chemotherapy.

Indexed as

AgedAntineoplastic AgentsCarcinoma, Non-Small-Cell LungCisplatinDisease-Free SurvivalFemaleFibrinogenHumansKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedPlatinum CompoundsProportional Hazards ModelsROC CurveSerum AlbuminAntineoplastic AgentsCisplatinFibrinogenPlatinum CompoundsSerum AlbuminAlbumin-to-fibrinogen ratioChemotherapyNon small-cell lung cancersPrognosis

Identifiers

PMID30925910
PMCPMC6441182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.